Fundraising Fox
Jade Biosciences
2 known investors
Find your way into Jade Biosciences
Sign up to see every warm intro you have to Jade Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Jade Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Jade Biosciences develops therapeutic antibodies targeting autoimmune diseases, with a lead candidate in clinical development for immunoglobulin A nephropathy, a chronic kidney disease. The company's pipeline includes additional candidates designed to modulate immune system responses in autoimmune conditions.
Investors · 2
Funding
SEC filings, press & company announcements- Undisclosed amountpublic offeringJun 2026Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Founder mafia
2 people who came through Jade Biosciences went on to found or lead other companies.
Acquisitions · 1
Early investors' stakes continue via these dealsAerovate Therapeutics was a clinical-stage biopharmaceutical company developing AV-101, an inhaled dry-powder imatinib formulation for pulmonary arterial hypertension. After its lead drug failed Phase IIb trials, it merged into Jade Biosciences via a reverse merger to continue as a public company.
Frequently asked questions
- What does Jade Biosciences do?
- Jade Biosciences develops therapeutic antibodies targeting autoimmune diseases, with a lead candidate in clinical development for immunoglobulin A nephropathy, a chronic kidney disease. The company's pipeline includes additional candidates designed to modulate immune system responses in autoimmune conditions.
- Who are Jade Biosciences's investors?
- Jade Biosciences's investors include Foresite Capital, Frazier Life Sciences.